HMG CoA reductase inhibitor treatment induces dysglycemia in renal allograft recipients

Eun Yeong Choe, Hye Jin Wang, Obin Kwon, Yongin Cho, Kyu Ha Huh, Myoung Soo Kim, Yu Seun Kim, Chul Woo Ahn, Bong Soo Cha, Hyun Chul Lee, Eun Seok Kang

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

BACKGROUND: Dysglycemia and dyslipidemia are important metabolic complications of organ transplantation. Statins are widely used to control dyslipidemia; however, long-term use of statins is related to diabetes mellitus (DM) and impaired fasting glucose (IFG). The aim of this study was to evaluate the influence of statins on the development of dysglycemia (IFG and/or DM) in renal allograft recipients. METHODS: A total of 394 patients without previously known DM or IFG who underwent kidney transplantation were enrolled. Patients were grouped into the two groups according to the use of statin (control, n=149; statin, n=245). The major statins used were fluvastatin (80 mg/d, n=134) and atorvastatin (20 mg/d, n=111). We compared the incidence of IFG or DM during the follow-up period. RESULTS: The incidence of IFG was higher in the statin group than that in the control group (28.6% vs. 8.7%, P<0.001). The incidence of dysglycemia was significantly higher in the statin group (40.0% vs. 15.4%, P=0.001). Time to development of dysglycemia after transplantation was shorter in the statin group than in the control group (38.8±29.7 vs. 47.2±23.3 months, P=0.002). Statin use was associated with an increased risk for dysglycemia after adjustment for age, sex, body mass index, hypertension, cholesterol levels, hepatitis C infection, and type of immunosuppressant (hazard ratio=3.08, 95% confidence interval=1.91-4.98). The dysglycemic effect was more profound in the patients who used atorvastatin than in those who used fluvastatin (hazard ratio=2.21, 95% confidence interval=1.02-4.76). CONCLUSION: Statin treatment is associated with an elevation in fasting plasma glucose and in the development of dysglycemia in renal allograft recipients.

Original languageEnglish
Pages (from-to)419-425
Number of pages7
JournalTransplantation
Volume97
Issue number4
DOIs
Publication statusPublished - 2014 Feb 27

All Science Journal Classification (ASJC) codes

  • Transplantation

Fingerprint Dive into the research topics of 'HMG CoA reductase inhibitor treatment induces dysglycemia in renal allograft recipients'. Together they form a unique fingerprint.

  • Cite this

    Choe, E. Y., Wang, H. J., Kwon, O., Cho, Y., Huh, K. H., Kim, M. S., Kim, Y. S., Ahn, C. W., Cha, B. S., Lee, H. C., & Kang, E. S. (2014). HMG CoA reductase inhibitor treatment induces dysglycemia in renal allograft recipients. Transplantation, 97(4), 419-425. https://doi.org/10.1097/01.TP.0000437427.04733.ad